Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Illidge

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Blood|March 28, 2007
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantationFranck Morschhauser, Tim Illidge, Damien Huglo, et al.
Leukemia & Lymphoma|June 11, 2014
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphomaTim Illidge, Reda Bouabdallah, Robert Chen, et al.
Frontiers in Immunology|June 12, 2023
The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapyJamie Frankish, Debayan Mukherjee, Erminia Romano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II studyBarbara Pro, Ranjana Advani, Pauline Brice, et al.
International Journal of Radiation Oncology, Biology, Physics|February 12, 2015
Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the International Lymphoma Radiation Oncology GroupMaja V Maraldo, Bouthaina S Dabaja, Andrea R Filippi, et al.
The New England Journal of Medicine|April 23, 2015
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphomaJohn Radford, Tim Illidge, Nicholas Counsell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2019
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID StudySally F Barrington, Elizabeth H Phillips, Nicholas Counsell, et al.
Blood|October 5, 2017
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphomaBarbara Pro, Ranjana Advani, Pauline Brice, et al.
Blood|March 7, 2018
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomasMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Blood|March 28, 2007
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantationFranck Morschhauser, Tim Illidge, Damien Huglo, et al.
Leukemia & Lymphoma|June 11, 2014
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphomaTim Illidge, Reda Bouabdallah, Robert Chen, et al.
Frontiers in Immunology|June 12, 2023
The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapyJamie Frankish, Debayan Mukherjee, Erminia Romano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II studyBarbara Pro, Ranjana Advani, Pauline Brice, et al.
International Journal of Radiation Oncology, Biology, Physics|February 12, 2015
Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the International Lymphoma Radiation Oncology GroupMaja V Maraldo, Bouthaina S Dabaja, Andrea R Filippi, et al.
The New England Journal of Medicine|April 23, 2015
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphomaJohn Radford, Tim Illidge, Nicholas Counsell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2019
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID StudySally F Barrington, Elizabeth H Phillips, Nicholas Counsell, et al.
Blood|October 5, 2017
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphomaBarbara Pro, Ranjana Advani, Pauline Brice, et al.
Blood|March 7, 2018
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomasMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Pageof 7